The Blood-borne MiRNA Signature of Lung Cancer Patients is Independent of Histology but Influenced by Metastases

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2014 Sep 2

PMID 25175044

Citations 19

Authors

Petra Leidinger

Christina Backes

Michael Blatt

Andreas Keller

Hanno Huwer

Philipp Lepper

Robert Bals

Eckart Meese

Affiliations

Soon will be listed here.

Abstract

Objectives: In our previous studies we reported a panel of 24 miRNAs that allowed discrimination between blood of lung tumor patients independent of the histological subtype and blood of healthy controls with an accuracy of 95.4% [94.9%-95.9%]. Here, we now separately analyzed the miRNA expression in blood of non-small cell lung cancer (NSCLC), including squamous cell lung cancer and adenocarcinoma, and small cell lung cancer (SCLC) patients.

Patients And Methods: In total, we examined the expression levels of 1,205 miRNAs in blood samples from 20 patients from each of the three histological groups and determined differentially expressed miRNAs between histological subtypes and metastatic and non-metastatic lung cancer. We further determined the overlap of miRNAs expressed in each subgroup with the 24-miRNA signature of lung tumor patients.

Results: Based on a raw p-value < 0.05, only 18 blood-borne miRNAs were differentially expressed between patients with adenocarcinoma and with squamous cell lung carcinoma, 11 miRNAs between adenocarcinoma and SCLC, and 2 between squamous cell lung carcinoma and SCLC. Likewise, the comparison based on a fold change of 1.5 did not reveal major differences of the blood-borne miRNA expression pattern between NSCLC and SCLC. In addition, we found a large overlap between the blood-borne miRNAs detected in the three histological subgroups and the previously described 24-miRNA signature that separates lung cancer patients form controls. We identified several miRNAs that allowed differentiating between metastatic and non-metastatic tumors both in blood of patients with adenocarcinoma and in blood of patients with SCLC.

Conclusion: There is a common miRNA expression pattern in blood of lung cancer patients that does not allow a reliable further subtyping into NSCLC or SCLC, or into adenocarcinoma and squamous cell lung cancer. The previously described 24-miRNA signature for lung cancer appears not primarily dependent on histological subtypes. However, metastatic adenocarcinoma and SCLC can be predicted with 75% accuracy.

Citing Articles

Identification and Application of Emerging Biomarkers in Treatment of Non-Small-Cell Lung Cancer: Systematic Review.

Restrepo J, Martinez Guevara D, Pareja Lopez A, Montenegro Palacios J, Liscano Y Cancers (Basel). 2024; 16(13).

PMID: 39001401 PMC: 11240412. DOI: 10.3390/cancers16132338.

Converging peripheral blood microRNA profiles in Parkinson's disease and progressive supranuclear palsy.

Pavelka L, Rauschenberger A, Hemedan A, Ostaszewski M, Glaab E, Kruger R Brain Commun. 2024; 6(3):fcae187.

PMID: 38863572 PMC: 11166179. DOI: 10.1093/braincomms/fcae187.

A Glimmer of Hope for Patients with a T3 Transformation Zone: miRNAs Are Potential Biomarkers for Cervical Dysplasia.

Wittenborn J, Flasshove E, Kupec T, Najjari L, Stickeler E, Maurer J Diagnostics (Basel). 2023; 13(24).

PMID: 38132183 PMC: 10742976. DOI: 10.3390/diagnostics13243599.

Increased levels of microRNA-320 in blood serum and plasma is associated with imminent and advanced lung cancer.

Nost T, Skogholt A, Urbarova I, Mjelle R, Paulsen E, Donnem T Mol Oncol. 2022; 17(2):312-327.

PMID: 36337027 PMC: 9892825. DOI: 10.1002/1878-0261.13336.

Current Status and Future Perspectives of Liquid Biopsy in Small Cell Lung Cancer.

Mondelo-Macia P, Garcia-Gonzalez J, Leon-Mateos L, Castillo-Garcia A, Lopez-Lopez R, Muinelo-Romay L Biomedicines. 2021; 9(1).

PMID: 33430290 PMC: 7825645. DOI: 10.3390/biomedicines9010048.

References

Keller A, Backes C, Leidinger P, Kefer N, Boisguerin V, Barbacioru C . Next-generation sequencing identifies novel microRNAs in peripheral blood of lung cancer patients. Mol Biosyst. 2011; 7(12):3187-99. DOI: 10.1039/c1mb05353a. View

Zhang Y, Zhu W, He J, Chen D, Huang Y, Le H . miRNAs expression profiling to distinguish lung squamous-cell carcinoma from adenocarcinoma subtypes. J Cancer Res Clin Oncol. 2012; 138(10):1641-50. DOI: 10.1007/s00432-012-1240-0. View

Cortez M, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood A, Calin G . MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011; 8(8):467-77. PMC: 3423224. DOI: 10.1038/nrclinonc.2011.76. View

Bishop J, Benjamin H, Cholakh H, Chajut A, Clark D, Westra W . Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res. 2010; 16(2):610-9. DOI: 10.1158/1078-0432.CCR-09-2638. View

Scheff R, Schneider B . Non-small-cell lung cancer: treatment of late stage disease: chemotherapeutics and new frontiers. Semin Intervent Radiol. 2014; 30(2):191-8. PMC: 3710022. DOI: 10.1055/s-0033-1342961. View

Huang W, Hu J, Yang D, Fan X, Jin Y, Hou Y . Two microRNA panels to discriminate three subtypes of lung carcinoma in bronchial brushing specimens. Am J Respir Crit Care Med. 2012; 186(11):1160-7. DOI: 10.1164/rccm.201203-0534OC. View

Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y . Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol. 2010; 28(10):1721-6. DOI: 10.1200/JCO.2009.24.9342. View

Lackey A, Donington J . Surgical management of lung cancer. Semin Intervent Radiol. 2014; 30(2):133-40. PMC: 3710020. DOI: 10.1055/s-0033-1342954. View

Scott W, Howington J, Feigenberg S, Movsas B, Pisters K . Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007; 132(3 Suppl):234S-242S. DOI: 10.1378/chest.07-1378. View

10.

Jeong H, Kim E, Lee J, Lee J, Yoo H, Kim J . Aberrant expression of let-7a miRNA in the blood of non-small cell lung cancer patients. Mol Med Rep. 2011; 4(2):383-7. DOI: 10.3892/mmr.2011.430. View

11.

Grilley-Olson J, Hayes D, Moore D, Leslie K, Wilkerson M, Qaqish B . Validation of interobserver agreement in lung cancer assessment: hematoxylin-eosin diagnostic reproducibility for non-small cell lung cancer: the 2004 World Health Organization classification and therapeutically relevant subsets. Arch Pathol Lab Med. 2012; 137(1):32-40. PMC: 5787023. DOI: 10.5858/arpa.2012-0033-OA. View

12.

Russo F, Di Bella S, Nigita G, Macca V, Lagana A, Giugno R . miRandola: extracellular circulating microRNAs database. PLoS One. 2012; 7(10):e47786. PMC: 3477145. DOI: 10.1371/journal.pone.0047786. View

13.

Leidinger P, Keller A, Borries A, Huwer H, Rohling M, Huebers J . Specific peripheral miRNA profiles for distinguishing lung cancer from COPD. Lung Cancer. 2011; 74(1):41-7. DOI: 10.1016/j.lungcan.2011.02.003. View

14.

Lebanony D, Benjamin H, Gilad S, Ezagouri M, Dov A, Ashkenazi K . Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol. 2009; 27(12):2030-7. DOI: 10.1200/JCO.2008.19.4134. View

15.

Stang A, Pohlabeln H, Muller K, Jahn I, Giersiepen K, Jockel K . Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study. Lung Cancer. 2006; 52(1):29-36. DOI: 10.1016/j.lungcan.2005.11.012. View

16.

Dragan A, Rosca E, Vaida T . Correlations between the results of the histological and cytological examination in the diagnostic of the broncho-pulmonary cancer. Rom J Morphol Embryol. 2006; 46(4):311-5. View

17.

Del Vescovo V, Cantaloni C, Cucino A, Girlando S, Silvestri M, Bragantini E . miR-205 Expression levels in nonsmall cell lung cancer do not always distinguish adenocarcinomas from squamous cell carcinomas. Am J Surg Pathol. 2011; 35(2):268-75. DOI: 10.1097/PAS.0b013e3182068171. View

18.

Cortez M, Calin G . MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther. 2009; 9(6):703-711. DOI: 10.1517/14712590902932889. View

19.

Keller A, Leidinger P, Borries A, Wendschlag A, Wucherpfennig F, Scheffler M . miRNAs in lung cancer - studying complex fingerprints in patient's blood cells by microarray experiments. BMC Cancer. 2009; 9:353. PMC: 2764731. DOI: 10.1186/1471-2407-9-353. View

20.

Feinstein A, GELFMAN N, YESNER R . Observer variability in the histopathologic diagnosis of lung cancer. Am Rev Respir Dis. 1970; 101(5):671-84. DOI: 10.1164/arrd.1970.101.5.671. View